New Haven, Conn.A protein measured in a simple blood test may be a new biomarker to identify patients with the most serious form of asthma, Yale School of Medicine scientists report today in the New England Journal (NEJM).

Identifying this new biomarker, YKL-40, brings researchers one step closer to a therapy for the nations 2.5 million asthmatics with a severe form of the disease that is difficult to treat, the scientists say.

The studies were done in collaboration with researchers in Wisconsin, France, and at MedImmune Inc.

Asthma is a chronic disease of the lung that affects more than 30 million Americans, among them nine million children. Typically it is characterized by chronic inflammation and structural changes in the airwayssymptoms that are severe in some patients and mild in others. Investigators are trying to find ways to control the inflammation and to understand the variation in severity.

The scientists reviewed serum levels of YKL-40 in 253 adults patients in three asthma and control groups at Yale, the University of Wisconsin, and the University of Paris. The found increased circulating serum levels of YKL-40 in patients with asthma in comparison to those without disease. In addition, blood levels of YKL-40 correlated with asthma severity, lung function, and thickness of the patients bronchial wall.

The results demonstrate that YKL-40 is significantly elevated in severe asthma, said Geoffrey Chupp, M.D., associate professor of medicine at Yale and the lead author on the study. Having a blood test to characterize asthmatics will be useful in pursuing asthma research and potentially in managing asthma.

He said that research on the biology of YKL-40 should be incorporated into investigations on the pathogenesis of asthma, and additional studies are needed to define the potential role of a YKL-40 blood test in asthma management.

Jack Elias, M.D., professor and chair of medicine, professor of immunobiology, and senior author of the study, said the findings are among the first to define a parameter for asthma that can be assessed with a blood test.

This may allow us to identify a subpopulation of patients with severe asthma and give us insights into the biologic processes that make the disease so severe in these individuals, Elias said. Our studies also have demonstrated that eliminating YKL-40 decreases specific types of tissue inflammationwhich could be of particular benefit to asthmatic patients with an elevated level of this protein.


Posted by: Rose    Source

---